MAM
Madison bags real estate developer Neelkanth creative
MUMBAI: Sam Balsara’s Madison is on a roll. After pocketing a gaggle of accounts and being ranked as among the top media agencies in the country, it is the turn of its Creative to get into the act. Madison Creative has bagged the creative account of real estate developer Neelkanth. The size of the new acquisition was not known at the time of writing.
Says Neelkanth group knowledge worker Mukesh. M. Patel in an official commuinque, “We were looking for an agency that could provide us sound strategic advice and give us creatives that could project the strength and values of Neelkanth group that our prospective buyers could relate to. We decided on Madison Creative after we got the confidence that they are capable of meeting our requirements.”
Madison Communications executive director Prabha Prabhu says “We are delighted with the win of Neelkanth Group. It is a very challenging category, since in the real estate business, one expects immediate results even from release of a single ad.”
Madison Creative’s win of Neelkanth account follows the wins of those of Deccan Chronicle, Forbes Yellow Pages and Smart photography in the last two months, states in the media release.
Madison Creative is the full service agency of Madison World which also has specialist units in Media, PR, Outdoor, Rural, Retail and Entertainment with 375 communication professionals working in 8 cities across India.
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
